Coronavirus Vaccine: Bangavax and two other vaccines to meet human trial conditions
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Saturday
July 19, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SATURDAY, JULY 19, 2025
Bangavax and two other vaccines to meet human trial conditions

Covid-19 in Bangladesh

TBS Report
16 June, 2021, 02:15 pm
Last modified: 16 June, 2021, 08:46 pm

Related News

  • Bangavax gets DGDA nod for human trials
  • Globe Biotech publishes Bangavax results of tests on monkeys
  • Indian Covaxin to be permitted for trial in Bangladesh
  • TBS Today: Bangavax trials face scientific and ethical concerns
  • NZ regulator approves Pfizer vaccine for 12-15 year olds

Bangavax and two other vaccines to meet human trial conditions

Globe Biotech and two Indian and Chinese drugmakers must submit documents on the effectiveness and side effects of the vaccines on monkeys

TBS Report
16 June, 2021, 02:15 pm
Last modified: 16 June, 2021, 08:46 pm
Logo of Globe Biotech Limited. Picture: Collected
Logo of Globe Biotech Limited. Picture: Collected

The Bangladesh Medical Research Council (BMRC) has set conditions for the human trial of three more coronavirus vaccines, including local drugmaker Globe Biotech's Bangavax, and two others from China and India respectively.

Before "human trials", the institutes will have to fulfil all conditions as per BMRC rules.

The decision was made at a meeting of the National Research Ethics Committee of the BMRC on Wednesday morning.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"We have decided in principle to approve the three vaccines. But they must meet certain conditions," BMRC Director, Professor Dr Ruhul Amin, told journalists after the meeting.

"All documents on the effectiveness and side effects of these vaccines on monkeys or chimpanzees must be submitted to the BMRC prior to Phase-1 trials. The issue of safety in human use will be seriously considered. If these rules are followed, we will definitely approve."

In addition to Bangavax, it has been decided in principle to approve the applications of Bharat Biotech and the Vero cell vaccine by the Institute of Medical Biology, Chinese Academy of Medical Sciences.

Two icddr,b scientists sought approval for the Chinese and Indian vaccines, and Globe Biotech for Bangavax.

Dr Ruhul Amin said, "It is not that the Globe vaccine has received approval for a clinical trial. But we are positive, even though several issues have been raised, including safety issues."

He said the three companies that have applied for first and second phase clinical trials will be informed of the Bangladesh Medical Research Council's (BMRC) decision.

"If necessary, the Contract Research Organisations (CROs) of the three companies can be called at any time to know the current status of the institutes," he added.

On 28 December, Globe Biotech, a Bangladeshi biotech firm, got approval from the Directorate General of Drug Administration (DGDA) to produce Covid-19 vaccine candidate Bangavax to carry out clinical trials.

On 16 January it submitted its trial protocol to the BMRC for the clinical trials of its Covid-19 vaccine, Bangavax.

Earlier, the company on 5 October 2020, noted that vaccine trials on rabbits and mice had shown "very promising results."

Bangladesh has so far approved the emergency use of six vaccines – Oxford-AstraZeneca, Sinopharm of China, Sputnik-V of Russia, Pfizer-BioNTech, CronaVac of China, and Johnson & Johnson.

Bangladesh / Top News

BMRC / conditonally / approves / human trial / Bangavax

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Tarique Rahman. Sketch: TBS
    Tarique urges all to stay alert against election sabotage plot
  • Jamaat-e-Islami Ameer Dr Shafiqur Rahman spoke at the party's first national rally at Suhrawardy Udyan in the capital today (19 July). Photo: Rajib Dhar
    No extortion or corruption if Jamaat voted to power: Shafiqur at Suhrawardy rally
  • Economist Dr Debapriya Bhattacharya. File photo: UNB
    Autocracy removed, yet hesitation to speak freely remains: Debapriya

MOST VIEWED

  • Chief Adviser Muhammad Yunus and SpaceX Vice President Lauren Dreyer after a meeting at state guest house Jamuna on 18 July 2025. Photo: Focus Bangla
    SpaceX VP Lauren Dreyer praises Bangladesh's efficiency in facilitating Starlink launch
  • Representational Photo: Collected
    Railway allocates special trains for Jamaat's national rally in Dhaka
  • Governments often rely on foreign loans. Russia’s loans covered 90% of the Rooppur Nuclear Power plant project's cost. Photo: Collected
    Loan tenure for Rooppur plant extended 
  • Representational image. Photo: Unsplash
    Mobile operators give 1GB free data to users observing 'Free Internet Day' today
  • Dollar rate falling fast – what it means for the economy
    Dollar rate falling fast – what it means for the economy
  • Chattogram-based Western Marine Shipyard Ltd has exported two tugboats—Ghaya and Khalid—to UAE-based Marwan Shipping Ltd, earning $1.6 million. The vessels were officially handed over at the Chittagong Boat Club on 17 July. Photo: Courtesy
    Refined sugar imports double in FY25 as duty cuts bite local refiners

Related News

  • Bangavax gets DGDA nod for human trials
  • Globe Biotech publishes Bangavax results of tests on monkeys
  • Indian Covaxin to be permitted for trial in Bangladesh
  • TBS Today: Bangavax trials face scientific and ethical concerns
  • NZ regulator approves Pfizer vaccine for 12-15 year olds

Features

Jatrabari in the capital looks like a warzone as police, alongside Chhatra League men, swoop on quota reform protesters. Photo: Mehedi Hasan

19 July 2024: At least 148 killed as government attempts to quash protests violently

22h | Panorama
Illustration: TBS

Curfews, block raids, and internet blackouts: Hasina’s last ditch efforts to cling to power

1d | Panorama
The Mymensingh district administration confirmed that Zamindar Shashikant Acharya Chowdhury built the house near Shashi Lodge for his staff. Photo: Collected

The Mymensingh house might not belong to Satyajit Ray's family, but there’s little to celebrate

1d | Panorama
Illustration: TBS

20 years of war, 7.5m tonnes of bombs, 1.3m dead: How the US razed Vietnam to the ground

1d | The Big Picture

More Videos from TBS

After Gopalganj, the reason why NCP is facing obstacles in Cox's Bazar?

After Gopalganj, the reason why NCP is facing obstacles in Cox's Bazar?

26m | TBS Today
What does Jamaat Nayeb Ameer Abdullah Taher say about reforms?

What does Jamaat Nayeb Ameer Abdullah Taher say about reforms?

41m | TBS Today
The tendency of central banks to buy gold is increasing worldwide.

The tendency of central banks to buy gold is increasing worldwide.

1h | Others
Sarjisra’s Message at Jamaat’s Suhrawardy Udyan’s assembly

Sarjisra’s Message at Jamaat’s Suhrawardy Udyan’s assembly

1h | TBS Today
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net